ReviewNature reviews. Clinical oncology2024

Antiangiogenic-immune-checkpoint inhibitor combinations: lessons from phase III clinical trials.

Hung-Yang Kuo et al.PubMed ↗Publisher ↗

No numbers read from the abstract.